Merck: to present progress in hematology at ASH
(CercleFinance.com) - Merck announces the presentation of over 20 abstracts on both approved and investigational drugs at the annual meeting of the American Society of Hematology (ASH), to be held in San Diego, US, on 7-10 December.
Presentations will include Zilovertamab vedotin (MK-2140) in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma; Nemtabrutinib (MK-1026) in follicular and marginal lymphoma; Bomedemstat (MK-3543) and updated data on Keytruda (pembrolizumab) in low-risk classical Hodgkin lymphoma.
Merck therefore confirms its commitment to addressing unmet medical needs in hematological neoplasms through innovative therapeutic approaches.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Presentations will include Zilovertamab vedotin (MK-2140) in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma; Nemtabrutinib (MK-1026) in follicular and marginal lymphoma; Bomedemstat (MK-3543) and updated data on Keytruda (pembrolizumab) in low-risk classical Hodgkin lymphoma.
Merck therefore confirms its commitment to addressing unmet medical needs in hematological neoplasms through innovative therapeutic approaches.
Copyright (c) 2024 CercleFinance.com. All rights reserved.